Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74


Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Gökbuget N, Kantarjian HM, Brüggemann M, Stein AS, Bargou RC, Dombret H, Fielding AK, Heffner L, Rigal-Huguet F, Litzow M, O'Brien S, Zugmaier G, Gao S, Nagorsen D, Forman SJ, Topp MS.

Blood Adv. 2019 Oct 22;3(20):3033-3037. doi: 10.1182/bloodadvances.2019000457.


Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients.

Nicolini FE, Dulucq S, Boureau L, Cony-Makhoul P, Charbonnier A, Escoffre-Barbe M, Rigal-Huguet F, Coiteux V, Varet B, Dubruille V, Lenain P, Rousselot P, Rea D, Guerci-Bresler A, Legros L, Liu J, Gardembas M, Ianotto JC, Turlure P, Johnson-Ansah H, Martiniuc J, Jardel H, Joly B, Zunic P, Henni T, Villemagne B, Berger MG, Cayssials E, Guilhot F, Larosa F, Guilhot J, Etienne G, Mahon FX.

Clin Cancer Res. 2019 Nov 15;25(22):6606-6613. doi: 10.1158/1078-0432.CCR-18-3373. Epub 2019 Jul 10.


Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Rea D, Ame S, Berger M, Cayuela JM, Charbonnier A, Coiteux V, Cony-Makhoul P, Dubruille V, Dulucq S, Etienne G, Legros L, Nicolini F, Roche-Lestienne C, Escoffre-Barbe M, Gardembas M, Guerci-Bresler A, Johnson-Ansah H, Rigal-Huguet F, Rousselot P, Mahon FX; French Chronic Myeloid Leukemia Study Group.

Cancer. 2018 Jul 15;124(14):2956-2963. doi: 10.1002/cncr.31411. Epub 2018 May 3.


Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

Etienne G, Guilhot J, Rea D, Rigal-Huguet F, Nicolini F, Charbonnier A, Guerci-Bresler A, Legros L, Varet B, Gardembas M, Dubruille V, Tulliez M, Noel MP, Ianotto JC, Villemagne B, Carré M, Guilhot F, Rousselot P, Mahon FX.

J Clin Oncol. 2017 Jan 20;35(3):298-305. doi: 10.1200/JCO.2016.68.2914. Epub 2016 Oct 31.


Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia.

Johnson-Ansah H, Guilhot J, Rousselot P, Rea D, Legros L, Rigal-Huguet F, Nicolini FE, Mahon FX, Preudhomme C, Guilhot F.

Cancer. 2013 Dec 15;119(24):4284-9. doi: 10.1002/cncr.28328. Epub 2013 Sep 16.


Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC).

N Engl J Med. 2010 Dec 23;363(26):2511-21. doi: 10.1056/NEJMoa1004095.


Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.

Nicolini FE, Hayette S, Legros L, Rousselot P, Maloisel F, Tulliez M, Guerci A, Charbonnier A, Prébet T, Rigal-Huguet F, Chabane K, Magaud JP, Paillet C, Pivot C, Michallet M.

Leuk Res. 2011 Jan;35(1):80-6. doi: 10.1016/j.leukres.2010.04.010. Epub 2010 Jun 3.


[Guidelines for the management of nilotinib (Tasigna)-induced side effects in chronic myelogenous leukemia: recommendations of French Intergroup of CML (Fi-LMC group)].

Etienne G, Milpied B, Réa D, Rigal-Huguet F, Tulliez M, Nicolini FE; French Intergroup of CML (Fi-LMC group).

Bull Cancer. 2010 Aug;97(8):997-1009. doi: 10.1684/bdc.2010.1136. French.


Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.

Kelaidi C, Chevret S, De Botton S, Raffoux E, Guerci A, Thomas X, Pigneux A, Lamy T, Rigal-Huguet F, Meyer-Monard S, Chevallier P, Maloisel F, Deconinck E, Ferrant A, Fegueux N, Ifrah N, Sanz M, Dombret H, Fenaux P, Adès L.

J Clin Oncol. 2009 Jun 1;27(16):2668-76. doi: 10.1200/JCO.2008.18.4119. Epub 2009 May 4.


[Guidelines for the management of dasatinib (Sprycel)-induced side effects in chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemias].

Cony-Makhoul P, Bergeron A, Corm S, Dubruille V, Rea D, Rigal-Huguet F, Nicolini FE.

Bull Cancer. 2008 Sep;95(9):805-11. doi: 10.1684/bdc.2008.0703. French.


Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group.

Adès L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Maloisel F, Deconinck E, Ferrant A, Thomas X, Fegueux N, Chomienne C, Dombret H, Degos L, Fenaux P; European Acute Promyelocytic Leukemia Group.

J Clin Oncol. 2006 Dec 20;24(36):5703-10. Epub 2006 Nov 20.


Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study.

Delannoy A, Delabesse E, Lhéritier V, Castaigne S, Rigal-Huguet F, Raffoux E, Garban F, Legrand O, Bologna S, Dubruille V, Turlure P, Reman O, Delain M, Isnard F, Coso D, Raby P, Buzyn A, Caillères S, Darre S, Fohrer C, Sonet A, Bilhou-Nabera C, Béné MC, Dombret H, Berthaud P, Thomas X.

Leukemia. 2006 Sep;20(9):1526-32. Epub 2006 Jul 13.


Expression of beta-catenin by acute myeloid leukemia cells predicts enhanced clonogenic capacities and poor prognosis.

Ysebaert L, Chicanne G, Demur C, De Toni F, Prade-Houdellier N, Ruidavets JB, Mansat-De Mas V, Rigal-Huguet F, Laurent G, Payrastre B, Manenti S, Racaud-Sultan C.

Leukemia. 2006 Jul;20(7):1211-6. Epub 2006 May 11.


Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials).

Kelaidi C, Ades L, Chevret S, Sanz M, Guerci A, Thomas X, de Botton S, Raffoux E, Rayon C, Fegueux N, Bordessoule D, Rigal-Huguet F, Link H, Stoppa A, Vekhoff A, Meyer-Monard S, Castaigne S, Dombret H, Degos L, Fenaux P.

Leukemia. 2006 May;20(5):905-7. No abstract available.


Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials.

Dhédin N, Dombret H, Thomas X, Lhéritier V, Boiron JM, Rigal-Huguet F, Vey N, Kuentz M, Reman O, Witz F, Delannoy A, Kovacsovics T, Bradstock K, Charrin C, Boucheix C, Gabert J, Blaise D, Fière D, Vernant JP.

Leukemia. 2006 Feb;20(2):336-44.


[Cardiac effects of cytokines produced after rituximab infusion].

Tournamille JF, Rigal-Huguet F, Pathak A, Montastruc JL, Lapeyre-Mestre M.

Bull Cancer. 2005 Sep;92(9):769-71. French.


Early allogeneic stem-cell transplantation for young adults with acute myeloblastic leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT experience.

Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F, Molina L, Fegueux N, Pigneux A, Recher C, Rossi JF, Attal M, Sotto JJ, Maraninchi D, Reiffers J, Bardou VJ, Esterni B, Blaise D.

J Clin Oncol. 2005 Oct 20;23(30):7676-84. Epub 2005 Sep 26.


Prognostic implication of FLT3 and Ras gene mutations in patients with acute promyelocytic leukemia (APL): a retrospective study from the European APL Group.

Callens C, Chevret S, Cayuela JM, Cassinat B, Raffoux E, de Botton S, Thomas X, Guerci A, Fegueux N, Pigneux A, Stoppa AM, Lamy T, Rigal-Huguet F, Vekhoff A, Meyer-Monard S, Ferrand A, Sanz M, Chomienne C, Fenaux P, Dombret H; European APL Group.

Leukemia. 2005 Jul;19(7):1153-60.


One versus two high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission.

Jourdan E, Rigal-Huguet F, Marit G, Vey N, Dastugue N, Fegueux N, Molina L, Gastaut JA, Legros L, Zerazhi H, Cailleres S, Bauduer F, Bordessoule D, Attal M, Blaise D, Pigneux A; BGMT Study Group.

Br J Haematol. 2005 May;129(3):403-10.


Dysphagia revealing esophageal involvement by non-Hodgkin's lymphoma.

Astudillo L, Peron JM, Sailler L, Danjoux M, Rigal-Huguet F, Arlet-Suau E.

Ann Hematol. 2005 Jul;84(7):482-3. Epub 2005 Apr 7. No abstract available.


Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.

Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Cheron N, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J, Guilhot F; CML French Group.

Blood. 2003 Dec 15;102(13):4298-305. Epub 2003 Aug 21.


Myelodysplastic syndrome after acute promyelocytic leukemia: the European APL group experience.

Lobe I, Rigal-Huguet F, Vekhoff A, Desablens B, Bordessoule D, Mounier C, Ferrant A, Sanz M, Fey M, Chomienne C, Chevret S, Degos L, Fenaux P; European APL group experience.

Leukemia. 2003 Aug;17(8):1600-4.


Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.

Guilhot F, Gardembas M, Rousselot P, Tulliez M, Vigier M, Buzyn A, Rigal-Huguet F, Legros L, Michallet M, Berthou C, Najman A, Maloisel F, Mahon FX, Facon T, Berthaud P, Guilhot J; CML French Group.

Semin Hematol. 2003 Apr;40(2 Suppl 2):92-7. Review.


Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.

Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Dombret H; French Acute Myeloid Leukemia Intergroup; Groupe Ouest-Est des Leucémies Aiguës Myéoblastiques; Leucémies Aiguës Myéoblastiques de l'Enfant; Acute Leukemia French Association; Bordeaux-Grenoble-Marseille-Toulouse cooperative groups.

Blood. 2003 Jul 15;102(2):462-9. Epub 2003 Mar 20. Review.


Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS.

Brassat D, Recher C, Waubant E, Le Page E, Rigal-Huguet F, Laurent G, Edan G, Clanet M.

Neurology. 2002 Sep 24;59(6):954-5.


Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia--results of the prospective multicenter LALA-94 trial.

Dombret H, Gabert J, Boiron JM, Rigal-Huguet F, Blaise D, Thomas X, Delannoy A, Buzyn A, Bilhou-Nabera C, Cayuela JM, Fenaux P, Bourhis JH, Fegueux N, Charrin C, Boucheix C, Lhéritier V, Espérou H, MacIntyre E, Vernant JP, Fière D; Groupe d'Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l'Adulte (GET-LALA Group).

Blood. 2002 Oct 1;100(7):2357-66.


A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup.

Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thomas X, Rigal-Huguet F, Lioure B, Auvrignon A, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Socié G, Dombret H.

Blood. 2002 May 15;99(10):3517-23.


Sweet's syndrome associated with retinoic acid syndrome in a patient with promyelocytic leukemia.

Astudillo L, Loche F, Reynish W, Rigal-Huguet F, Lamant L, Pris J.

Ann Hematol. 2002 Feb;81(2):111-4. Epub 2002 Jan 10.


A randomized prospective multicentre trial of cefpirome versus piperacillin-tazobactam in febrile neutropenia.

Bauduer F, Cousin T, Boulat O, Rigal-Huguet F, Molina L, Fegueux N, Jourdan E, Boiron JM, Reiffers J; BGMT Collaborative Group.

Leuk Lymphoma. 2001 Jul;42(3):379-86.


[Concerning the article "Sickle cell anemia and pregnancy: systematic prophylactic transfusions"].

Salque C, Berrebi A, Alie-daram S, Ayoubi JM, Rigal-Huguet F.

J Gynecol Obstet Biol Reprod (Paris). 2001 Sep;30(5):484. French. No abstract available.


[Sickle cell anemia and pregnancy: considerations on systematic prophylactic transfusion].

Salque C, Berrebi A, Alie-Daram S, Ayoubi JM, Rigal-Huguet F.

J Gynecol Obstet Biol Reprod (Paris). 2001 Apr;30(2):160-5. French. Erratum in: J Gynecol Obstet Biol Reprod (Paris) 2001 Sep;30(5):484.


PCR analysis of immunoglobulin heavy chain (IgH) and TcR-gamma chain gene rearrangements in the diagnosis of lymphoproliferative disorders: results of a study of 525 cases.

Thériault C, Galoin S, Valmary S, Selves J, Lamant L, Roda D, Rigal-Huguet F, Brousset P, Delsol G, Al Saati T.

Mod Pathol. 2000 Dec;13(12):1269-79.


Hepatosplenic alphabeta T-cell lymphoma: an unusual case with clinical, histologic, and cytogenetic features of gammadelta hepatosplenic T-cell lymphoma.

Suarez F, Wlodarska I, Rigal-Huguet F, Mempel M, Martin-Garcia N, Farcet JP, Delsol G, Gaulard P.

Am J Surg Pathol. 2000 Jul;24(7):1027-32.


High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease.

Drouet E, Brousset P, Fares F, Icart J, Verniol C, Meggetto F, Schlaifer D, Desmorat-Coat H, Rigal-Huguet F, Niveleau A, Delsol G.

J Med Virol. 1999 Apr;57(4):383-9.


Chromosome 8 tetrasomies and pentasomies--a clonal abnormality closely associated with acute monocytic leukaemia.

Lessard M, Herry A, Berthou C, Léglise MC, Abgrall JF, Luquet I, Dastugue N, Duchayne E, Rigal-Huguet F, Lafage M, Sainty D, Reiffers J, Bernard P.

Leuk Lymphoma. 1997 Sep;27(1-2):127-35.


Location of the BCR-ABL fusion gene on the 9q34 band in two cases of Ph-positive chronic myeloid leukemia.

Aurich J, Dastugue N, Duchayne E, Schlaifer D, Rigal-Huguet F, Caballin MR.

Genes Chromosomes Cancer. 1997 Oct;20(2):148-54.


[Inefficacy of exchange-transfusion in case of a methotrexate poisoning].

Bénézet S, Chatelut E, Bagheri H, Rigal-Huguet F, Nguyen L, Pourrat J, Robert A, Montastruc JL, Canal P.

Bull Cancer. 1997 Aug;84(8):788-90. French.


A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2; 5 translocation.

Delsol G, Lamant L, Mariamé B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, al Saati T, Cerretti DP, Morris SW, Mason DY.

Blood. 1997 Mar 1;89(5):1483-90.


[Kikuchi syndrome, cytomegalovirus infection and lupus].

Adoue D, Rauzy O, Rigal-Huguet F.

Rev Med Interne. 1997;18(4):338. French. No abstract available.


Bcl-x gene expression in Hodgkin's disease.

Schlaifer D, Krajewski S, Rigal-Huguet F, Laurent G, Pris J, Delsol G, Reed JC, Brousset P.

Leuk Lymphoma. 1996 Sep;23(1-2):143-6.


Immunodetection of apoptosis-regulating proteins in lymphomas from patients with and without human immunodeficiency virus infection.

Schlaifer D, Krajewski S, Galoin S, Rigal-Huguet F, Laurent G, Massip P, Pris J, Delsol G, Reed JC, Brousset P.

Am J Pathol. 1996 Jul;149(1):177-85.


Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease.

Brousset P, Benharroch D, Krajewski S, Laurent G, Meggetto F, Rigal-Huguet F, Gopas J, Prinsloo I, Pris J, Delsol G, Reed JC, Schlaifer D.

Blood. 1996 Mar 15;87(6):2470-5.


T-cell gamma-delta lymphoproliferative disorders after renal transplantation.

Rostaing L, Tkaczuk J, Rigal-Huguet F, Lloveras JJ, Durand D.

Transplant Proc. 1995 Apr;27(2):1774-5. No abstract available.


Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols.

Soussain C, Patte C, Ostronoff M, Delmer A, Rigal-Huguet F, Cambier N, Leprisé PY, François S, Cony-Makhoul P, Harousseau JL, et al.

Blood. 1995 Feb 1;85(3):664-74.


Epstein-Barr virus in familial Hodgkin's disease.

Schlaifer D, Rigal-Huguet F, Robert A, Attal M, Abbal M, Fonck Y, Laurent G, Pris J, Delsol G, Brousset P.

Br J Haematol. 1994 Nov;88(3):636-8.


Intensified conditioning regimen with busulfan followed by allogeneic BMT in children with myelodysplastic syndromes.

Rubie H, Attal M, Demur C, Brousset P, Duchayne E, Rigal-Huguet F, Dastugue N, Robert A.

Bone Marrow Transplant. 1994 Jun;13(6):759-62.


B-cell lymphoma following polycythemia vera: evidence for the involvement of two different clones.

Schlaifer D, Dastugue N, Brousset P, Delsol G, Muller C, Rigal-Huguet F, Attal M, Laurent G, Pris J.

Leukemia. 1994 May;8(5):895-6.


Effectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m2) in acute promyelocytic leukemia.

Castaigne S, Lefebvre P, Chomienne C, Suc E, Rigal-Huguet F, Gardin C, Delmer A, Archimbaud E, Tilly H, Janvier M, et al.

Blood. 1993 Dec 15;82(12):3560-3.


Supplemental Content

Loading ...
Support Center